|Day Low/High||45.95 / 45.99|
|52 Wk Low/High||22.11 / 46.01|
Some widely held stocks have dropped 10% in the past 24 hours. Portfolio Manager David Peltier discussed what he's buying.
It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.
Sales of short bowel syndrome drug Gattex have been strong despite worries over price, says Francois Nader CEO of NPS Pharmaceuticals.
Jim Cramer discusses NPS Pharma and its orphan drug franchise with Nicole Urken, Mad Money Research Director.
U.S. stocks continue to trade higher on Tuesdays in 2013, as investors shift their focus away from Cyprus. Portfolio Manager David Peltier highlights early trading action.
Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.
Portfolio manager David Peltier discusses how to play one the most volatile low-dollar stocks of 2012.
Join Portfolio Mgr. David Peltier @davidspeltier on Twitter Thursday at 4:30 pm ET, for his #SU10chat
Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.
Francois Nader, CEO of NPS Pharmaceuticals, says the market is realizing the potential of its Gattex and Natpara drugs.